{
    "clinical_study": {
        "@rank": "62101", 
        "arm_group": [
            {
                "arm_group_label": "Albuterol", 
                "arm_group_type": "Experimental", 
                "description": "Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study."
            }, 
            {
                "arm_group_label": "Placebo Comparator", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study the study team proposes to investigate the efficacy of albuterol on motor\n      function of individuals with Late Onset Pompe Disease (LOPD) who are receiving enzyme\n      replacement therapy, given albuterol was well-tolerated in patients with Late Onset Pompe\n      Disease."
        }, 
        "brief_title": "Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy", 
        "condition": "Pompe Disease", 
        "condition_browse": {
            "mesh_term": "Glycogen Storage Disease Type II"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of Pompe disease by blood acid alpha-glucosidase assay and acid\n             alpha-glucosidase gene sequencing,\n\n          2. Age: 18+ years at enrollment.\n\n          3. Receiving enzyme replacement therapy at standard dose (20 mg/kg every 2 weeks) for at\n             least 52 weeks.\n\n          4. Subjects are capable of giving written consent.\n\n          5. 6 minute walk test latency <85% of expected.\n\n          6. Forced vital capacity >15% of expected (supine).\n\n        Exclusion Criteria:\n\n          1. Continuous invasive ventilation (via tracheostomy or endotracheal tube).\n\n          2. Clinically relevant illness within two weeks of enrollment including fever > 38.2 C,\n             vomiting more than once in 24 hours, seizure, or other symptom deemed\n             contraindicative to new therapy.\n\n          3. Chronic heart disease (Myocardial infarction, arrythmia, cardiomyopathy).\n\n          4. History of seizure disorder.\n\n          5. History of diabetes.\n\n          6. Hypokalemia.\n\n          7. History of hyperthyroidism.\n\n          8. Pregnancy.\n\n          9. Patients on a non-standard schedule for enzyme replacement therapy; for example,\n             weekly infusions as opposed to infusions every two weeks.\n\n         10. Anti-rhGAA antibody titer > 1:100,000\n\n         11. History of hypersensitivity to Beta 2-agonist drugs such as albuterol, levalbuterol\n             (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol\n             (Serevent)..\n\n         12. The use of the following medications:\n\n               -  diuretics (water pill);\n\n               -  digoxin (digitalis, Lanoxin);\n\n               -  beta-blockers such as atenolol (Tenormin), metoprolol (Lopressor), and\n                  propranolol (Inderal);\n\n               -  tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin\n                  (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor);\n\n               -  Monoamine oxidase inhibitors such as isocarboxazid (Marplan), phenelzine\n                  (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine\n                  (Parnate); or\n\n               -  bronchodilators such as albuterol, levalbuterol (Xopenex), bitolterol\n                  (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol\n                  (Serevent), isoetherine (Bronkometer), metaproterenol (Alupent, Metaprel), or\n                  isoproterenol (Isuprel Mistometer) within 12 weeks prior to enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885936", 
            "org_study_id": "Pro00046020"
        }, 
        "intervention": [
            {
                "arm_group_label": "Albuterol", 
                "description": "Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.", 
                "intervention_name": "Albuterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Albuterol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "LOPD", 
            "Pompe Disease"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "koebe001@mc.duke.edu", 
                "last_name": "Dwight Koeberl, MD", 
                "phone": "919-684-2036"
            }, 
            "contact_backup": {
                "email": "crista.walters@duke.edu", 
                "last_name": "Crista Walters, NP", 
                "phone": "919-681-1945"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Dwight Koeberl, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Dwight d Koeberl, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with Adverse Events.", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885936"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "22154081", 
            "citation": "Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. \u03b22 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab. 2012 Feb;105(2):221-7. doi: 10.1016/j.ymgme.2011.11.005. Epub 2011 Nov 11."
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in forced vital capacity from pulmonary function tests at 30 weeks and 52 weeks.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and weeks 30 and 52."
            }, 
            {
                "description": "Assessed by physical therapist", 
                "measure": "Change in 6 minute walk test", 
                "safety_issue": "No", 
                "time_frame": "Weeks 6 and 52."
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}